Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.

نویسندگان

  • N L Liberato
  • S Quaglini
  • G Barosi
چکیده

PURPOSE To evaluate the cost-effectiveness of interferon alfa (IFN alpha) treatment of patients with chronic myelogenous leukemia relative to conventional chemotherapy. MATERIALS AND METHODS A decision-analysis model that involved a multistate Markov process was designed to estimate the expected cost and quality-adjusted life expectancies for two cohorts of patients to be administered conventional chemotherapy or IFN alpha. Two IFN alpha strategies were modeled: prolonged treatment for patients who achieved a hematologic response (scenario A) or only for patients who achieved a cytogenetic remission in a 2-year period (scenario B). Data on response and transition probabilities between health states were obtained from the literature by a MEDLINE search and pooled with a meta-analytic method. Costs were based on local charges. Expected survival was adjusted for quality of life on the basis of an expert panel judgment. RESULTS Baseline analysis showed IFN alpha treatment to increase the quality-adjusted life expectancy by 15.5 and 12.5 months relative to conventional chemotherapy, in scenarios A and B, respectively. Marginal cost-effectiveness was $89,500 and $63,500 per quality-adjusted life-year (QALY) gained. Sensitivity analysis confirmed IFN alpha as the most effective approach. Cost-effectiveness results were sensitive to the cost of IFN alpha therapy and to the assumptions about the rate of cytogenetic remission. Reducing the drug dose, as suggested by a recent report, would decrease the marginal cost-effectiveness to less than $20,000. CONCLUSION IFN alpha is substantially superior to conventional chemotherapy in terms of quality-adjusted survival, but, at the current doses, marginal cost-effectiveness ranges from $50,000 to $100,000 per QALY gained under most of our assumptions.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pregnancy Outcome of Two Patients with Chronic Myelogenous Leukemia Treated with Imatinib

Although chronic myelogenous leukemia in pregnancy is rare, its management and treatment is more difficult and complicated.Treatment of patients with chronic myelogenous leukemia includes bone marrow transplantation, however in less than 30% of patients the donor’s organ would be accepted. To this end, cytotoxic therapy is considered as an alternative therapeutic option. This option provides sa...

متن کامل

Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon alpha.

متن کامل

GRUNWALD-LETNIKOV SCHEME FOR SYSTEM OF CHRONIC MYELOGENOUS LEUKEMIA FRACTIONAL DIFFERENTIAL EQUATIONS AND ITS OPTIMAL CONTROL OF DRUG TREATMENT

In this article, a mathematical model describing the growth orterminating myelogenous leukemia blood cancer's cells against naive T-celland eective T-cell population of body, presented by fractional dierentialequations. We use this model to analyze the stability of the dynamics, whichoccur in the local interaction of eector-immune cell and tumor cells. Wewill also investigate the optimal contro...

متن کامل

Function of Neutrophils in Different Phases of Chronic Myelogenous Leukemia

In chronic myelogenous leukemia (CML), the mature granulocytes originate from a stem cell line harboring an abnormal chromosome, therefore it is possible that metabolic-functional abnormalities occur in the morphologically mature cells. In the present study, the phagocytic activity including intracellular killing, nitro blue tetrazolium (NBT) reduction, and phagocytosis were studied in 37 CML p...

متن کامل

-resistant Chronic Myelogenous Leukemia Patients Interferon-stimulated Genes in Interferon-sensitive and Updated Version

a-Interferon induces hematological and cytogenetic remissions in some individuals with newly diagnosed Philadelphia-positive chronic myelogenous leukemia. However, interferon-resistant disease occurs in a con sistent patient subset (primary resistance) and develops during therapy in additional patients (secondary resistance). Several o-interferon-inducible genes have been characterized. In inte...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology

دوره 15 7  شماره 

صفحات  -

تاریخ انتشار 1997